Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder

RJT Mocking1, I Harmsen1, J Assies1, MWJ Koeter1, HG Ruhé1,2,5 and AH Schene3,4,5

Omega-3 polyunsaturated fatty acid (PUFA) supplementation has been proposed as (adjuvant) treatment for major depressive disorder (MDD). In the present meta-analysis, we pooled randomized placebo-controlled trials assessing the effects of omega-3 PUFA supplementation on depressive symptoms in MDD. Moreover, we performed meta-regression to test whether supplementation effects depended on eicosapentaenoic acid (EPA) or docosahexaenoic acid dose, their ratio, study duration, participants’ age, percentage antidepressant users, baseline MDD symptom severity, publication year and study quality. To limit heterogeneity, we only included studies in adult patients with MDD assessed using standardized clinical interviews, and excluded studies that specifically studied perinatal/perimenopausal or comorbid MDD. Our PubMed/EMBASE search resulted in 1955 articles, from which we included 13 studies providing 1233 participants. After taking potential publication bias into account, meta-analysis showed an overall beneficial effect of omega-3 PUFAs on depressive symptoms in MDD (standardized mean difference = 0.398 (0.114–0.682), P = 0.006, random-effects model). As an explanation for significant heterogeneity (I² = 73.36, P < 0.001), meta-regression showed that higher EPA dose (β = 0.00037 (0.00009–0.00065), P = 0.009), higher percentage antidepressant users (β = 0.0058 (0.0017–0.0114), P = 0.044) and earlier publication year (β = −0.0735 (-0.143 to 0.004), P = 0.04) were significantly associated with better outcome for PUFA supplementation. Additional sensitivity analyses were performed. In conclusion, present meta-analysis suggested a beneficial overall effect of omega-3 PUFA supplementation in MDD patients, especially for higher doses of EPA and in participants taking antidepressants. Future precision medicine trials should establish whether possible interactions between EPA and antidepressants could provide targets to improve antidepressant response and its prediction. Furthermore, potential long-term biochemical side effects of high-dosed add-on EPA supplementation should be carefully monitored.

INTRODUCTION

Omega-3 polyunsaturated fatty acids (PUFAs) have been proposed as a treatment for major depressive disorder (MDD). Over the last decade, several meta-analyses have been performed, which suggested variable degrees of beneficial effects of omega-3 PUFAs for MDD, but made critical remarks regarding the quality of the evidence and possible publication bias.1–6 These meta-analyses evoked academic correspondence, discussing the used inclusion criteria and selection of outcome measures.7–8 In brief, this correspondence suggested beneficial effects (1) if a higher ratio of omega-3 PUFA eicosapentaenoic acid (EPA) to docosahexaenoic acid (DHA) was being supplemented2 and (2) only in patients with actual MDD as opposed to subjects with merely depressive symptoms.8

Of these meta-analyses, only the three most recent meta-analyses covered the research performed over the last 5 years: (1) Grosso et al.9 included randomized controlled trials (RCTs) published up to August 2013, and concluded that omega-3 PUFAs were effective in depressive patients with or without an MDD diagnosis; (2) Yang et al.10 pooled RCTs published up to March 2015 on the effect of the combination of EPA and DHA on depression in women and observed a beneficial effect; and (3) Appleton et al.11 performed a Cochrane meta-analysis of RCTs published up to May 2015, concluding that there is a small-to-moderate, non-clinically beneficial effect of omega-3 PUFAs.

Importantly, these meta-analyses seem to have several issues of interest. First, they did not correct for potential publication bias, for example, by using the trim-and-fill method.17 Second, Grosso et al. included two comparisons of the study of Jazayeri et al.12 This study had three arms using a double-dummy technique (EPA+placebo vs EPA+fluoxetine vs fluoxetine+placebo). Although other meta-analyses only included the fluoxetine+EPA vs fluoxetine+placebo comparison (that is, EPA vs placebo in an add-on design), Grosso et al. additionally included the EPA+placebo vs fluoxetine+placebo comparison (that is, EPA vs fluoxetine during additional placebo treatment). Thereby, Grosso et al. not only compared EPA vs placebo, but additionally included a comparison of EPA vs active antidepressant medication, potentially reducing the overall effect size. Third, Grosso et al. and Yang et al. included three articles that all seem to report on the same RCT,13–15 that is, (partial) duplicate publication which distorts pooled-effect
estimates. Fourth, Grosso et al. and Appleton et al. missed potentially important evidence by not including all RCTs on MDD patients in their analysis (for example, Lesperance et al.\textsuperscript{16} in Grosso et al.; and Mozaffari-Khosravi et al.\textsuperscript{17} in Appleton et al.). Although the study of Mozaffari-Khosravi et al. included mild-to-moderate MDD patients, all patients fulfilled MDD criteria, baseline severity was comparable to other included studies and other included studies (for example, Lucas et al.\textsuperscript{18}) also used an upper limit for MDD severity. Fifth, all three meta-analyses only used post-intervention effect size data, while repeated measures are available, which may improve effect size estimation precision. Sixth, by including RCTs that not only included MDD patients but also patients with dysthymia,\textsuperscript{13,14} all three meta-analyses did not specifically focus on MDD only. In addition, Appleton et al. included the trial by Peet and Horrobin\textsuperscript{19} that did not use MDD diagnosis as an inclusion criterion, but rather a cutoff score on a depression symptom questionnaire. Moreover, Appleton et al. and Grosso et al. also included trials on subjects with MDD secondary to neurological or other somatic disorders (for example, Da Silva et al.),\textsuperscript{20} which may increase heterogeneity due to different underlying pathophysiology.

Therefore, our study aims at continuing the academic debate by performing a revised updated meta-analysis on the effectiveness of omega-3 PUFAs for the treatment of MDD taking into account the above issues of concern. In addition, we performed meta-regression analyses to explain expected heterogeneity, by testing the effects of EPA and DHA dose and their ratio, study duration, participants’ age, percentage antidepressant users, baseline MDD symptom severity, publication year and study quality.

**MATERIALS AND METHODS**

**Search strategy**

We performed a search in the Medline and Embase databases (from inception up to 8 December 2015). We used a search strategy combining terms regarding MDD and fatty acid supplementation using Boolean operators (See Supplementary Methods). We additionally searched references of selected studies and earlier meta-analyses for potential studies.\textsuperscript{4,9}

**Study selection**

Two independent reviewers (RJTM and IH/JA) screened the identified articles for their relevance by title and abstract, and—if necessary—the full text. In case of disagreement between reviewers, inclusion could be conclusively determined by discussion in all the cases. A priori criteria for inclusion of studies were: (1) design was a randomized placebo-controlled trial; (2) inclusion of adult patients with MDD according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) as assessed by a standardized clinical interview. We excluded studies that (1) specifically studied perinatal or perimenopausal MDD or (2) MDD secondary to other neuropsychiatric disorders.

With these in- and exclusion criteria, we aimed to test the effect of omega-3 fatty acid supplementation on depressive symptoms specifically in MDD, as opposed to depressive symptoms in the general population (including subclinical depression). Because previous meta-analyses included clinically more heterogeneous populations which theoretically may preclude meta-analysis, we aimed to prevent inclusion of trials where supplementation of omega-3 fatty acids could improve an underlying somatic or (neuro)psychiatric disorder, with a secondary effect on the depression scores. In addition, by excluding specific subgroups like perinatal or perimenopausal MDD, with a potentially different pathophysiology, we aimed to further minimize heterogeneity among included studies. Because of the widespread comorbidity between MDD and cardiovascular disease, we did not exclude studies that specifically studied MDD with comorbid cardiovascular disease or diabetes.

Nevertheless, we performed sensitivity analyses without the studies that specifically studied MDD with comorbid cardiovascular disease or diabetes.\textsuperscript{22,23}

**Critical appraisal**

We assessed the quality of the studies that were selected with the in- and exclusion criteria above using the Jadad scale for reporting RCTs.\textsuperscript{24}

**Data extraction**

Two independent reviewers (RJTM and IH) extracted the data into specifically designed spreadsheets. We collected the data on descriptors, methods and outcomes. Possible disagreements were resolved by discussion with a third independent reviewer where necessary (JA).

We used the primary outcome measure reported by the study. We used the unadjusted intention-to-treat repeated-measures statistics where available. If multiple primary outcomes were reported, we used the Hamilton Depression Rating Scale (HDRS).\textsuperscript{25} If unavailable, we used another clinician-rated outcome. If unavailable, we used a self-rated depression scale. We performed sensitivity analyses using unpublished additional data derived from the authors where available.\textsuperscript{6,12,26,27}

**Statistical analysis**

We performed the statistical analyses with Comprehensive Meta-Analysis version 2. We used standardized mean differences as the summary statistic for meta-analysis. We assessed heterogeneity by calculating the $I^2$ statistic.\textsuperscript{11} Given the expected heterogeneity, we a priori used a random-effects model.\textsuperscript{11} We performed the sensitivity analyses using fixed-effects models because they are considered to be less vulnerable for publication bias. We assessed publication bias by plotting a funnel plot, and reporting the classic and Orwin’s fail-safe N, Begg and Mazumdar rank correlation and Egger’s regression intercept.\textsuperscript{11} Finally, we adjusted the values using the Duval and Tweedie’s trim-and-fill method.

We performed meta-regression using the method of moments computational option.\textsuperscript{11} We a priori planned to test the univariate effects of EPA and DHA dose, study duration, participants’ age, percentage antidepressant users, baseline MDD severity, publication year and study quality, on the effect size of trials. To compare EPA- and DHA-dose effects for studies where multiple subgroups were available, we regarded these subgroups as independent, assuming independence where necessary.\textsuperscript{11} For baseline severity, we converted scores to the 17-item Hamilton Depression Rating Scales using available conversion tables where needed.\textsuperscript{16,54}

**RESULTS**

**Selection of studies**

The search strategy resulted in 1955 articles for consideration in the present meta-analysis. The studies were excluded for several reasons, including not applying a randomized placebo-controlled trial design, no inclusion of subjects with MDD as ascertained by a structured clinical interview,\textsuperscript{30–33} or specifically including patients with perinatal or perimenopausal MDD, or MDD secondary to other neuropsychiatric disorders.\textsuperscript{20,34} (Supplementary Figure S1). After applying the in- and exclusion criteria, we included 15 studies,\textsuperscript{12,16–18,22,23,26,35–42} including a total of 1253 MDD subjects. Study-characteristics are provided in Supplementary Table 1. Of these 15 studies, 1 small preliminary study reports unpublished data (Coryell et al., related to Fiedorowicz et al.),\textsuperscript{42} and 1 small study has a considerable drop-out rate (>50%).\textsuperscript{61} Given the relatively preliminary nature of these two studies, we included them only in separate sensitivity analyses.

**Meta-analysis**

The meta-analysis on 13 RCTs in 1233 MDD subjects showed an overall beneficial effect of omega-3 PUFAs on depressive symptoms in MDD (standardized mean difference $= 0.398$ (0.114–0.682), $P = 0.006$, random-effects model, Figure 1). For the sensitivity analyses, see Supplementary Results.

**Publication bias**

The funnel plot for all the available data is shown in Supplementary Figure 2. The classic fail-safe N was 95, Orwin’s fail-safe N was 19 with criterion for a ‘trivial’ standardized
Our revised updated meta-analysis adds nuance to the ongoing debate on the effect of omega-3 PUFAs supplementation on depressive symptoms in MDD. By addressing several issues as noted in the introduction, the present meta-analysis studied effects of omega-3 PUFAs supplementation in all available evidence in a specific relatively homogeneous group of MDD subjects. Overall, with an standardized mean difference of 0.398, present meta-analysis shows a beneficial effect of omega-3 PUFAs that is comparable to effects reported in meta-analyses of antidepressants. Of note, this effect seemed larger in studies (1) supplementing higher doses of EPA and (2) performed in patients using antidepressants (augmentation/add-on), while it was independent of baseline depression severity or EPA/(EPA+DHA) ratio. However, more recent trials had smaller effect sizes, independent of trial quality.

By including a relatively homogeneous group of patients with MDD according to DSM criteria as assessed using a standardized clinical interview, we aimed to enhance internal validity and generalizability of the present meta-analysis. Nevertheless, the included MDD patients still form a heterogeneous group including both subjects that will benefit from omega-3 PUFAs supplementation and those that experience no or even negative effects. Several other unreported factors may influence the response to omega-3 PUFAs, which could not be tested in the present meta-analysis and meta-regression, for example, measurements of inflammation or nutrigenetics.

Nevertheless, we were able to test sample and trial-related factors that may influence omega-3 PUFAs response. In the present meta-analysis, response was independent of baseline MDD symptom severity. This may be because we included a relatively homogeneous sample of MDD patients in comparison with earlier meta-analyses that also included subjects with depressive symptoms. In contrast to the lack of effect of baseline severity, we noticed that the effects of supplementation seemed larger in patients being treated with antidepressants compared with patients not being concurrently treated with antidepressants. Of note, MDD baseline severity was not associated with percentage antidepressant use across trials. Therefore, this larger effect in trials where patients were being treated with antidepressants suggests an interaction between antidepressant use and omega-3 PUFAs at the biological level, for example, due to PUFAs influencing p-glycoprotein. It could be highly clinically relevant for understanding p-glycoprotein. It could be highly clinically relevant for understanding the effect of omega-3 PUFAs on neuronal membrane–antidepressant interactions or on inflammatory pathways. In addition, omega-3 PUFAs may interfere with serotonergic neurotransmission, or antidepressant transport across the blood–brain barrier by influencing p-glycoprotein. It could be highly clinically relevant to follow up on this finding that omega-3 PUFAs seem to have more effect in studies where participants use antidepressants, by further investigating the interaction between omega-3 PUFAs and inflammation or nutrigenetics.
and antidepressants from (integrated) biological and clinical perspectives.

The present meta-regression finding that higher EPA dose was associated with better response, nuances an earlier meta-analysis that observed significant effects after applying a dichotomous cutoff at 60% EPA content. First, although it remained relatively unclear how this previous cutoff was derived, our regression model suggested a linear relationship in all the available data without using an artificial cutoff. In addition, the present meta-analysis also showed that EPA/EPA+DHA ratio had no significant effect, nor had DHA dose. Altogether, this suggests that it is not the ratio of EPA vs DHA that is important, but rather the higher EPA dose. Although hypothesized, it does not seem that DHA counteracts the effects of EPA (for example, by competition for target proteins or membrane incorporation). DHA simply has not demonstrated a specific effect on the MDD symptoms. Nevertheless, it remains surprising that EPA seems to be responsible for the beneficial effects of omega-3 PUFA supplementation while DHA concentrations appear to differ more between patients and controls. In addition, the regression effect of EPA dose on RCT outcome depended to some extent on one trial that supplemented the highest EPA concentration. On the basis of these findings, it could be argued that the beneficial effects of omega-3 PUFA supplementation are not because supplementation corrects a membrane DHA ‘deficit’, but rather due to the anti-inflammatory characteristics of EPA’s oxidation products. Future mechanistic studies in a more continuous dose range should follow up on these findings.

However, these oxidation products may not have positive effects only. Relatively little is known about the precise role and effect of the great diversity of PUFA oxidation products. Although adverse events reported during the studies were usually mild and gastrointestinal in nature (for example, belching, constipation, fishy aftertaste), exposure to PUFA oxidation products with unknown effects may pose unknown risks in the long term. It may therefore be advisable to measure these oxidation products during future studies with a longer follow-up to obtain more insight in their potential toxicity. In addition, fishy aftertaste may result in unblinding, potentially distorting effect sizes.

The finding that more recent studies showed smaller effects remains puzzling. It seems independent from study quality, as we observed no association between study effect size and study quality operationalized as Jadad score. It may be that differences in background diet over time contributed to smaller effects of additional omega-3 PUFA supplementation. For example, even though studies usually excluded participants that used omega-3 PUFA supplements on their own initiative at baseline, it may be that participants started taking omega-3 PUFA supplements during the study owing to their increasing popularity, thereby diminishing outcome differences in more recent trials. Unfortunately, not enough trials provided uniform data regarding baseline omega-3 PUFA status or intake to formally test this, which would be interesting in future research.

Limitations and strengths

Despite several strengths of this meta-analysis, some limitations should be noted. First, the present meta-analysis has not been performed on patient level data. It would be interesting to confirm these findings on a patient level. Moreover, this may also lead to additional predictors of supplementation outcome, giving rise to extra targets for future precision medicine studies. We hope researchers will be motivated to share and pool available data in the future. Furthermore, while the present meta-analysis had enough power to detect small-to-medium effect sizes, smaller regression effects may have been lost as a result of the smaller number of studies due to the specific in- and exclusion criteria. In addition, several concerns regarding the quality of the available evidence could be made, like in most meta-analyses. Further high-quality evidence to support a beneficial effect of EPA in (antidepressant using) MDD patients could lead to more precise estimates of overall effect size. Finally, to maintain power for the meta-regression regarding the effect of percentage antidepressant users on supplementation outcome, we pooled all concurrent antidepressant classes together, while the effects may differ per class. It would be interesting to further test this in future studies including users of different antidepressants.

Nonetheless, the present study/analyses focused on studies that specifically included patients with MDD according to diagnostic criteria as ascertained with a structured clinical interview. We thus limited clinical heterogeneity while still maintaining a substantial overall sample size. As a second strength, by performing extensive nuanced a priori planned publication bias analyses and meta-regression analyses, we revealed new evidence for (1) an effect of EPA dose as opposed to EPA to DHA ratio and (2) an interaction between omega-3 PUFAs and antidepressants, both of which may be highly relevant for clinical practice.

Conclusion

In conclusion, the present meta-analysis observed a beneficial overall effect of omega-3 PUFA supplementation in patients with MDD according to diagnostic criteria, which seemed larger in studies that supplemented higher doses of EPA and included patients taking antidepressants. Future precision/personalized medicine trials should establish whether possible interactions between EPA and antidepressants could provide targets to improve antidepressant response and its prediction. Nevertheless, potential long-term biochemical side effects of high-dosed add-on EPA supplementation should be carefully monitored.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

RJTM is supported by a PhD scholarship from the Academic Medical Center of the University of Amsterdam. HGR is supported by an NWO/ZonMW VENI-Grant #016.126.059. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

REFERENCES


10 Yang JR, Han D, Qiao ZX, Tian Q, Qi D, Qiu XH. Combined application of ecosa-

pentaenoic acid and docosahexaenoic acid on depression in women: a meta-


12 Jazayeri S, Tehrani-Doost M, Keshavarz SA, Hosseini M, Djazayery A, Amini H et al. Comparison between the AA/EPA ratio in depressed and non depressed elderly females: omega-3 fatty acid supplementation correlates with improved symp-

toms but does not change immunological parameters. *Nutr J* **2012; 11**: 82.


14 Rondanelli M, Giascoa A, Opizzi A, Pelucchi C, La Vecchia C, Montorfano G et al. Long chain omega 3 polyunsaturated fatty acids supplementation in the treat-

ment of elderly depression: effects on depressive symptoms, on phospholipids fatty acids profile and on health-related quality of life. *J Nutr Health Aging* **2011; 15**: 37–44.


16 Mozaffari-Khosravi H, Yassini-Ardakani M, Karamati M, Shariat-Bafghi SE. Ecosa-


18 Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-

eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. *Arch Gen Psychiatry* **2002; 59**: 913–919.


22 Bot M, Pouwer F, Assies J, Jansen EH, Diamant M, Snoek FJ et al. Eicosapentaenoic acid as an add-on to antidepressant medication for co-morbid major depression in patients with diabetes mellitus: a randomized, double-blind placebo-


26 Koenig H, Conkin SM. Short-term supplementation of alpha-linolenic acid and docosahexaenoic acid on depression in women: a meta-


27 Ganzola S, Nierenberg AA, Schettler PJ, Kinkead BL, Fehling K, Martinson MA et al. A double-blind, randomized controlled clinical trial comparing ecosa-


29 Neufeld B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medicatio


32 Manzur LB, Martinez JM, Zboyan HA, Kertz B, Kim HF, Puryear LJ. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahex-

33 Gonzalez A, Mata S, Sanchez P, Gonzalez D, Urbina M, Fazzino F et al. Omega-3 fatty acids as adjunctive of antidepressant therapy and its effects on brain-

derived neurotrophic factor in serum, monocytes and lymphocytes. *Arch Vene-
zolanos Farmacol Ter* **2011; 30**: 72–78.


35 Chalkwijk S, Undurraga J, Tondo L, Baldessarini RJ. Declining efficacy in con-


Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)